Literature DB >> 15505370

The potential role of tau protein O-glycosylation in Alzheimer's disease.

Laura A Robertson1, Kenneth L Moya, Kieran C Breen.   

Abstract

Single O-linked N-acetylglucosamine (O-GlcNAc) sugar residues can compete with phosphate groups to occupy specific sites on certain nuclear and cytosolic proteins. Here we show that inhibiting cellular kinase activities resulted in changes in protein O-glycosylation levels in heat-stable cytoskeletal protein fractions derived from primary neuronal cells. As increased phosphorylation of the microtubule-associated protein tau is one of the pathological hallmarks of Alzheimer's disease and glycosylation may play an influential role in this process. We observed a significant decrease in the protein O-GlcNAc glycosylation of a tau-enriched cytoskeletal fraction generated from AD post-mortem brain samples as compared with control, suggesting an inverse relationship between the two post-translational modifications. Finally, cells transfected with the cDNA coding for O-GlcNAc transferase (OGT) displayed altered tau phosphorylation patterns as compared with control cells, suggesting that changes in tau glycosylation may influence its phosphorylation state. The specificity of the changes in the phosphorylation of individual amino acid residues provides evidence for a targeted O-glycosylation of tau.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15505370     DOI: 10.3233/jad-2004-6505

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  38 in total

Review 1.  Targeting tau protein in Alzheimer's disease.

Authors:  Cheng-Xin Gong; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Regulation of autophagy by protein post-translational modification.

Authors:  Willayat Yousuf Wani; Michaël Boyer-Guittaut; Matthew Dodson; John Chatham; Victor Darley-Usmar; Jianhua Zhang
Journal:  Lab Invest       Date:  2014-11-03       Impact factor: 5.662

Review 3.  Metabolic reserve as a determinant of cognitive aging.

Authors:  Alexis M Stranahan; Mark P Mattson
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 4.  Chemical approaches to understanding O-GlcNAc glycosylation in the brain.

Authors:  Jessica E Rexach; Peter M Clark; Linda C Hsieh-Wilson
Journal:  Nat Chem Biol       Date:  2008-02       Impact factor: 15.040

Review 5.  Therapeutic strategies for the treatment of tauopathies: Hopes and challenges.

Authors:  Mansi R Khanna; Jane Kovalevich; Virginia M-Y Lee; John Q Trojanowski; Kurt R Brunden
Journal:  Alzheimers Dement       Date:  2016-10       Impact factor: 21.566

6.  Effect of Phosphorylation and O-GlcNAcylation on Proline-Rich Domains of Tau.

Authors:  Lata Rani; Jeetain Mittal; Sairam S Mallajosyula
Journal:  J Phys Chem B       Date:  2020-03-02       Impact factor: 2.991

7.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

Authors:  Scott Miners; Emma Ashby; Shabnam Baig; Rachel Harrison; Hannah Tayler; Elizabeth Speedy; Jonathan A Prince; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2009-01-18       Impact factor: 4.060

Review 8.  Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.

Authors:  C-X Gong; K Iqbal
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

9.  D-Ribosylated Tau forms globular aggregates with high cytotoxicity.

Authors:  Lan Chen; Yan Wei; Xueqing Wang; Rongqiao He
Journal:  Cell Mol Life Sci       Date:  2009-06-11       Impact factor: 9.261

Review 10.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.